Sang-oh Han

1.1k total citations
27 papers, 896 citations indexed

About

Sang-oh Han is a scholar working on Molecular Biology, Physiology and Epidemiology. According to data from OpenAlex, Sang-oh Han has authored 27 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 14 papers in Physiology and 7 papers in Epidemiology. Recurrent topics in Sang-oh Han's work include Lysosomal Storage Disorders Research (14 papers), Trypanosoma species research and implications (7 papers) and Virus-based gene therapy research (5 papers). Sang-oh Han is often cited by papers focused on Lysosomal Storage Disorders Research (14 papers), Trypanosoma species research and implications (7 papers) and Virus-based gene therapy research (5 papers). Sang-oh Han collaborates with scholars based in United States, South Korea and France. Sang-oh Han's co-authors include Ram I. Mahato, Yong Kiel Sung, Dwight D. Koeberl, Sung Wan Kim, Songtao Li, Minhyung Lee, Anurag Maheshwari, Sudha K. Shenoy, Neil J. Freedman and Jiao‐Hui Wu and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Cell Biology and Journal of the American College of Cardiology.

In The Last Decade

Sang-oh Han

26 papers receiving 878 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sang-oh Han United States 14 648 309 158 90 83 27 896
Maria C. Edman United States 24 449 0.7× 166 0.5× 351 2.2× 165 1.8× 84 1.0× 52 1.4k
Anneke A. M. Janson Netherlands 14 1.9k 2.9× 510 1.7× 162 1.0× 81 0.9× 77 0.9× 18 2.1k
Eric Finn United States 13 862 1.3× 452 1.5× 78 0.5× 78 0.9× 54 0.7× 19 997
Shufeng Li China 17 438 0.7× 165 0.5× 57 0.4× 45 0.5× 29 0.3× 49 716
Matthias C. Huber Germany 17 500 0.8× 159 0.5× 43 0.3× 92 1.0× 40 0.5× 37 823
Timothy Connolly United States 13 812 1.3× 364 1.2× 36 0.2× 104 1.2× 39 0.5× 22 1.1k
Yixuan Wang China 20 1.1k 1.8× 159 0.5× 60 0.4× 57 0.6× 22 0.3× 49 1.4k
Noufϊssa Oudrhiri France 22 1.4k 2.1× 470 1.5× 74 0.5× 100 1.1× 20 0.2× 45 1.7k
Leslie C. Mounkes United States 13 1.6k 2.4× 322 1.0× 84 0.5× 93 1.0× 27 0.3× 18 1.7k
Renee C. Ryals United States 19 1.4k 2.2× 549 1.8× 35 0.2× 108 1.2× 89 1.1× 36 1.7k

Countries citing papers authored by Sang-oh Han

Since Specialization
Citations

This map shows the geographic impact of Sang-oh Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sang-oh Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sang-oh Han more than expected).

Fields of papers citing papers by Sang-oh Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sang-oh Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sang-oh Han. The network helps show where Sang-oh Han may publish in the future.

Co-authorship network of co-authors of Sang-oh Han

This figure shows the co-authorship network connecting the top 25 collaborators of Sang-oh Han. A scholar is included among the top collaborators of Sang-oh Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sang-oh Han. Sang-oh Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Han, Sang-oh, Mercedes Barzi, Haiqing Yi, et al.. (2025). High-potency MyoAAV capsids enhanced skeletal muscle correction in a mouse model of GSD IIIa. Molecular Therapy — Methods & Clinical Development. 33(3). 101567–101567.
2.
Smith, Edward C., Sam Hopkins, Laura E. Case, et al.. (2023). Phase I study of liver depot gene therapy in late-onset Pompe disease. Molecular Therapy. 31(7). 1994–2004. 24 indexed citations
3.
Han, Sang-oh, et al.. (2022). Minimum Effective Dose to Achieve Biochemical Correction with Adeno-Associated Virus Vector-Mediated Gene Therapy in Mice with Pompe Disease. Human Gene Therapy. 33(9-10). 492–498. 10 indexed citations
4.
5.
Jean‐Charles, Pierre‐Yves, Subhodeep Sarker, Sang-oh Han, et al.. (2022). A single phenylalanine residue in β-arrestin2 critically regulates its binding to G protein–coupled receptors. Journal of Biological Chemistry. 298(5). 101837–101837. 2 indexed citations
6.
Wang, Jason, Alastair Khodabukus, Sang-oh Han, et al.. (2021). Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease. Communications Biology. 4(1). 524–524. 26 indexed citations
7.
Han, Sang-oh, Songtao Li, Dennis Abraham, et al.. (2019). Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease. Molecular Genetics and Metabolism. 129(2). 73–79. 2 indexed citations
8.
Koeberl, Dwight D., Laura E. Case, Ankit K. Desai, et al.. (2019). Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease. Molecular Genetics and Metabolism. 129(2). 67–72. 13 indexed citations
9.
Han, Sang-oh, Songtao Li, Jeffrey I. Everitt, et al.. (2019). Comparisons of Infant and Adult Mice Reveal Age Effects for Liver Depot Gene Therapy in Pompe Disease. Molecular Therapy — Methods & Clinical Development. 17. 133–142. 13 indexed citations
10.
Koeberl, Dwight D., Laura E. Case, Edward C. Smith, et al.. (2018). Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease. Molecular Therapy. 26(9). 2304–2314. 25 indexed citations
11.
Han, Sang-oh, Giuseppe Ronzitti, Christian Leborgne, et al.. (2017). Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction. Molecular Therapy — Methods & Clinical Development. 4. 126–136. 60 indexed citations
12.
Han, Sang-oh, Songtao Li, Andrew Bird, & Dwight D. Koeberl. (2015). Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β 2 -Agonist in Murine Pompe Disease. Human Gene Therapy. 26(11). 743–750. 15 indexed citations
13.
Han, Sang-oh, et al.. (2015). A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease. Molecular Genetics and Metabolism. 117(2). 114–119. 12 indexed citations
14.
Oh, Yeonyee, et al.. (2012). Polyubiquitin Is Required for Growth, Development and Pathogenicity in the Rice Blast Fungus Magnaporthe oryzae. PLoS ONE. 7(8). e42868–e42868. 41 indexed citations
15.
Han, Sang-oh & William L. Miller. (2009). Activin A induces ovine follicle stimulating hormone beta using -169/-58 bp of its promoter and a simple TATA box. Reproductive Biology and Endocrinology. 7(1). 66–66. 6 indexed citations
16.
Fewell, Jason G., et al.. (2005). Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. Journal of Controlled Release. 109(1-3). 288–298. 45 indexed citations
17.
Day, John, Sheldon E. Litwin, David A. Bull, et al.. (2003). Novel gene therapy for post-myocardial infarction ventricular arrhythmias. Journal of the American College of Cardiology. 41(6). 105–105. 2 indexed citations
18.
Nah, Jae‐Woon, Lei Yu, Sang-oh Han, Cheol‐Hee Ahn, & Sung Wan Kim. (2002). Artery wall binding peptide-poly(ethylene glycol)-grafted-poly(l-lysine)-based gene delivery to artery wall cells. Journal of Controlled Release. 78(1-3). 273–284. 45 indexed citations
19.
Mahato, Ram I., Minhyung Lee, Sang-oh Han, Anurag Maheshwari, & Sung Wan Kim. (2001). Intratumoral Delivery of p2CMVmIL-12 Using Water-Soluble Lipopolymers. Molecular Therapy. 4(2). 130–138. 81 indexed citations
20.
Han, Sang-oh, et al.. (2000). Development of Biomaterials for Gene Therapy. Molecular Therapy. 2(4). 302–317. 319 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria C. Edman Breakdown of academic impact, for papers by Anneke A. M. Janson Breakdown of academic impact, for papers by Eric Finn Breakdown of academic impact, for papers by Shufeng Li Breakdown of academic impact, for papers by Matthias C. Huber Breakdown of academic impact, for papers by Timothy Connolly Breakdown of academic impact, for papers by Yixuan Wang Breakdown of academic impact, for papers by Noufϊssa Oudrhiri Breakdown of academic impact, for papers by Leslie C. Mounkes Breakdown of academic impact, for papers by Renee C. Ryals
Rankless by CCL
2026